Design Therapeutics, Inc. ROE

ROE of DSGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.

Highlights and Quick Summary

  • Annual ROE for 2022 was -17.85% (a -6.84% decrease from previous year)
  • Annual ROE for 2021 was -19.16% (a -117.3% decrease from previous year)
  • Annual ROE for 2020 was 110.72% (a 304.53% increase from previous year)
  • Twelve month ROE ending June 30, 2023 was -22.72% (a 11.92% increase compared to previous quarter)
  • Twelve month trailing ROE increased by 45.92% year-over-year
Trailing ROE for the last four month:
30 Jun '23 31 Mar '23 31 Dec '22 30 Sep '22
-22.72% -20.3% -17.85% -15.57%
Visit stockrow.com/DSGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Design Therapeutics, Inc.

Most recent ROEof DSGN including historical data for past 10 years.

Interactive Chart of ROE of Design Therapeutics, Inc.

Design Therapeutics, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 – – – – -17.85%
2021 – – – – -19.16%
2020 – – – – 110.72%
2019 – – – – 27.37%

Business Profile of Design Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com